Showing 4691-4700 of 6808 results for "".
- Krystal Biotech: Positive Interim Results in Phase 1/2 Trial of KB103https://practicaldermatology.com/news/krystal-biotech-positive-interim-results-in-phase-12-kb103-trial/2457562/
- Alastin Skincare's Latest Product May Become Body Contouring Procedures' New BFFhttps://practicaldermatology.com/news/alastin-skincares-latest-product-may-be-body-contouring-procedures-new-bff/2457573/
- FDA Clears Sebacia Microparticles for Laser-Based Acne Treatmenthttps://practicaldermatology.com/news/fda-clears-sebacia-microparticles-for-laser-based-acne-treatment/2457603/Sebacia Microparticles are now FDA-cleared for use in the treatment of acne. The clearance comes on the heels of a pivotal study demonstrating the clinical safety and efficacy of the micoparticles. Sebacia, Inc. had submitted its 510(k) submission to the FDA in June 2018. Sebacia Mic
- Latest on Compounding: FDA Proposes to Strike Three Bulk Drug Substances from Listhttps://practicaldermatology.com/news/latest-on-compounding-fda-proposes-to-strike-three-bulk-drug-substances-from-list/2457632/The FDA has issued a
- Consensus: Straight-Line Vector Planning Produces Best Silhouette InstaLift Resultshttps://practicaldermatology.com/news/consensus-straight-line-vector-planning-produces-best-silhouette-instalift-results/2457668/Straight-line vector planning produces the ideal lifting effect and sets the stage for maximum collagen regeneration with the Silhouette InstaLift, according to a study in the July 2018 issue of Journal of Drugs in Dermat
- Skin Cancer Risk Varies Based on Organ Transplant Patients' Skin Tonehttps://practicaldermatology.com/news/skin-cancer-risk-varies-based-on-organ-transplant-patients-skin-tone/2457673/Dermatologists must know how to evaluate organ transplant patients’ unique risk factors for skin cancer and counsel these patients accordingly. “Individuals who receive organ transplants need to take immunosuppressive medications for the rest of their lives, and this makes it
- Breaking News: Galderma Skinpact Awards Deadline Extended!https://practicaldermatology.com/news/breaking-news-galderma-skinpact-awards-deadline-extended/2457683/The new deadline for the Galderma Skinpact Awards is July 31, 2018. The awards are a social responsibility program by Galderma International in partnership with the Canadian Dermatology Association, and the Women's Dermatolo
- Older Melanoma Patients May Have Better Response to Immune Checkpoint Blockade Therapyhttps://practicaldermatology.com/news/older-melanoma-patients-may-have-better-response-to-immune-checkpoint-blockade-therapy/2457728/Patient age correlates with response to immunotherapy in melanoma, and depleting regulatory T cells in young patients may have a therapeutic potential to enhance response in younger patients, according to research from The Wistar Institute. Study resul
- PD1 Blocker Shrinks Advanced Squamous Cell Skin Cancershttps://practicaldermatology.com/news/pd1-blocker-shrinks-advanced-squamous-cell-skin-cancers/2457737/A checkpoint inhibitor shrinks the tumors of nearly half of patients with an incurable, advanced form of squamous cell carcinoma, an international team reports in the New England Journal of Medicine. “These results mark a potential paradigm shift in the treatment of pa
- With New Team, Revance Readies for Launch of their Botox Competitorhttps://practicaldermatology.com/news/with-new-team-revance-readies-for-launch-of-their-botox-competitor/2457819/With the advent of four new positions, Revance Therapeutics is expanding their commercialization team in anticipation of the product launch of for DaxibotulinumtoxinA for Injection (RT002) in the treatment of glabellar lines.